SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves selloff is being discussed alongside concerns about its heavy debt load, rising borrowing costs and whether AI demand and contract backlog can support its financing needs, with HSBCs bearish assessment adding to the pressure. Traders are split between viewing the balance-sheet risks and insider selling as reasons for further downside and arguing that strong demand, the backlog and Nvidia ties make the drop a buying opportunity.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Lilly is drawing attention after breaking to a new high, with traders linking the rally to European regulatory backing for its Foundayo obesity pill and broader optimism about its GLP-1 business. Bulls are celebrating the breakout and healthcares defensive appeal, while skeptics point to possible profit-taking, competition from Novo and the upcoming earnings report.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to record lows is fueling a heavily bearish conversation, with traders tying its political-proxy appeal to concerns about Trumps approval and the midterms, while questioning the companys business traction. A smaller bullish contingent sees a possible trading bounce and points to the pending TAE fusion deal as a potential pivot.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders react to elevated crude prices and fears that Middle East shipping or energy-infrastructure attacks could disrupt supply, while weighing possible diplomacy and Russian supply relief. The community is split between bulls focused on geopolitical risk and bears expecting the risk premium to fade, with some also warning that contract-roll effects and an extended run may amplify volatility.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers rally to a 52-week high is driving discussion, with traders citing momentum and rotation into defensive, dividend-paying pharma amid broader market weakness. Bulls see a potential breakout, while skeptics point to resistance and say a fresh company-specific catalyst is needed.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 trial in bipolar mania met its primary and secondary endpoints, drawing attention to the drugs potential but also to concerns about modest symptom improvement, agitation-related side effects, and discontinuations. Traders are divided, with some viewing the move as a fading bounce and adding shorts while others point to bullish analyst commentary.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicor is drawing attention after strong Q3 results and an upbeat outlook, with AI-related demand and growing Vertical Power Delivery royalty revenue reinforcing the growth story. Traders are weighing that strength against questions about one-time royalty catch-up payments, production capacity, and the earnings-per-share miss, contributing to a volatile reaction.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces quarterly results beat expectations and the company raised its outlook, but shares fell as traders weighed rising costs, weaker cash flow and a loss in its insurance business. The reaction has split the community between buyers calling the selloff unjustified after a strong report and bears focused on the cost pressures and weak price action.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is in focus amid volatile swings tied to a tech and AI-led selloff followed by a relief rebound. Traders disagree over whether the bounce can hold or is a bull trap, while concerns about AI funding and hedge-fund selling, rising oil and inflation, and upcoming megacap earnings add to uncertainty.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is selling off despite a third-quarter earnings and revenue beat and a new multiyear buyback, as traders focus on the narrowed profit outlook with its midpoint unchanged and declining U.S. sales and market share. Some see the decline as a buying opportunity given cash generation and capital returns, while others argue the outlook failed to justify the valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.

These Two Stocks Hit Fresh 52-Week Highs Today – DCTH Clocks Best Day In Nearly 15 Months

Equity

Delcath Systems announced a return to profitability after posting losses in the past two quarters, while Praxis’ second-quarter loss came in narrower than Wall Street had expected

TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme

Culper’s central allegation is that Tarsus has driven XDEMVY uptake among Medicare patients by funding copay assistance. 


Praxis Precision Medicines (PRAX) Shares Phase 2/3 POWER1 Study Findings

Praxis Precision Medicines (PRAX) Shares Phase 2/3 POWER1 Study Findings...

Praxis Reassesses Vormatrigine Program After Pivotal Epilepsy Study Misses Primary Endpoint

Praxis Precision Medicines reports mixed Phase 2/3 POWER1 results for vormatrigine, with higher-dose data showing stronger seizure reduction.read more...

PRAX Stock Drops 12% After Hours On Trial Setback — Retail Eyes FDA Approval Of Other Pipeline Candidates 

Praxis’s vormatrigine candidate failed to reduce the monthly frequency of focal onset seizures in certain patients in a trial. 


Moody Aldrich Partners LLC Buys New Position in Praxis Precision Medicines, Inc. $PRAX

Moody Aldrich Partners LLC bought a new stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 41,731 shares of the company's stock, valued a...

Pictet Asset Management Holding SA Makes New $71.09 Million Investment in Praxis Precision Medicines, Inc. $PRAX

Pictet Asset Management Holding SA bought a new position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 240,588 shares of the company's stock, valued at ap...

M&T Bank Corp Purchases Shares of 12,586 Praxis Precision Medicines, Inc. $PRAX

M&T Bank Corp purchased a new position in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 12,586 shares of the company's stock, valued at approximately...

Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Praxis Precision Medicines, Inc. $PRAX

Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 37,377 sha...

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>Delcath Systems raised its 2026 revenue guidance to $104 million to $108 million, up from its previous outlook of at least $100 million.</li><li>As of June 30, 2026, Delcath Systems had $95.9 million in cash and investments and no debt.</li><li>Praxis posted a loss of $2.87 per share, better than Wall Street’s estimates of a loss of $3.66 per share, according to Fiscal.ai.</li></ul>Shares of Delcath Systems (DCTH) and Praxis Precision Medicines (PRAX) hit fresh 52-week highs on Thursday, with DCTH recording its biggest single-day gains in nearly 15 months, after the companies posted better-than-expected second-quarter results.At the time of writing, <a href="https://stocktwits.com/symbol/DCTH">DCTH shares</a> traded 20% higher, having hit an intraday high of $15.62, while <a href="https://stocktwits.com/symbol/PRAX">PRAX stock</a> was up nearly 15%, after hitting an intraday high of $382.54.<h2 class="st-heading-2">DCTH Posts Profit After Two Quarters</h2>Delcath Systems reported better-than-expected second-quarter results, including a return to profitability after posting losses in the past two quarters. Revenue rose to $29.1 million from $24.2 million a year earlier, topping Wall Street estimates of $26.3 million, according to Fiscal.ai.The company posted earnings of $0.07 per share, compared with consensus estimates of a loss of $0.09 per share.Delcath Systems raised its 2026 revenue guidance to $104 million to $108 million, up from its previous outlook of at least $100 million. The company also expects full-year gross margins of 86% to 89%.As of June 30, 2026, Delcath Systems had $95.9 million in cash and investments and no debt.Retail sentiment surrounding DCTH on Stocktwits turned ‘bullish’ from ‘neutral’ over the past 24 hours, amid a 1,250% increase in message volumes. DCTH shares are up more than 53% so far this year.<h2 class="st-heading-2">PRAX’s Funds To Support Operations Till 2028</h2>Praxis Precision Medicines, a pre-revenue biotechnology firm, reported a second-quarter loss that was narrower than Wall Street expected, while ending the quarter with a cash position to support its pipeline through 2028.The company posted a net loss of $83.7 million, or $2.87 per share, better than Wall Street’s estimates of a loss of $3.66 per share, according to Fiscal.ai.Research and development expenses increased to $69.4 million from $63.0 million, primarily due to higher spending on its Solidus program, which is being developed to target rare and prevalent central nervous system (CNS) disorders, and increased personnel costs.As of June 30, 2026, Praxis held $1.4 billion in cash, cash equivalents, and marketable securities, up from $926.1 million at the end of 2025.Retail sentiment surrounding PRAX on Stocktwits flipped to ‘bullish’ from ‘bearish’ over the past 24 hours, amid ‘high’ message volumes. The stock is up more than 28% so far in 2026.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/ast-space-mobile-taps-vodafone-deutsche-telekom-orange-for-europe-expansion-asts-stock-heads-for-best-week-in-over-a-month/cZoB5cfRJJO">AST SpaceMobile Taps Vodafone, Deutsche Telekom, Orange For Europe Expansion – ASTS Stock Heads For Best Week In Over A Month</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

(Photo credit should read INDRANIL MUKHERJEE/AFP via Getty Images)

Delcath Systems Inc

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$264.82
Prev Close	$260.17
Open	$259.04
Dividend Yield	0.00%
50-Day Moving Average	$319.85
Beta	1.01
Avg. Volume	434,669.73
PE Ratio	-20.10

52-Week High	$392.70
52-Week Low	$154.45
Market Capitalization	$7.26B
EPS (Annual)	-$13.48
Price to Book	5.42
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

PRAX Fundamentals